Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Quantum Metric, the customer-driven digital analytics platform, today celebrates the one-year anniversary of its generative AI-powered solution, Felix AI.  Launched in April 2024, Felix AI has quickly ...

Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no ...

Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication ...

Corcept Therapeutics Inc is a commercial-stage ... advanced ovarian cancer, prostate cancer, ALS, and MASH. Market Capitalization Analysis: Falling below industry benchmarks, the company's market ...

Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym, the first medication ...

What is the current share price of Corcept Therapeutics (CORT)? Corcept Therapeutics's (CORT) current share price is $74.65. This constitutes a price movement of 36.65% when compared to the share ...